MedTrace Logo

Application of Remimazolam, Dexmedetomidine, and Esketamine in Pediatric Preoperative Sedation

NCT07050212 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-07-10

No results posted yet for this study

Summary

By comparing the application effects of three drugs in pediatric preoperative sedation, this study explores the optimal medication regimen, aiming to provide safer, more effective, and more personalized medication options for pediatric preoperative sedation. Additionally, this research will also focus on the impact of these three drugs on postoperative agitation in children, offering valuable references for the overall management of pediatric surgical anesthesia.

Conditions

  • Remimazolam
  • Dexmedetomidine
  • Esketamine

Interventions

DRUG

remimazolam group

remimazolam is administered intravenously at a dose of 0.3 mg/kg

DRUG

dexmedetomidine group

dexmedetomidine is administered intravenously at a dose of 1 μg/kg

DRUG

esketamine group

esketamine is administered intravenously at a dose of 0.5 mg/kg

Sponsors & Collaborators

  • Maternal and Child Health Hospital of Hubei Province

    lead OTHER

Principal Investigators

  • Na Li NaLi, MD · Maternal and Child Health Hospital of Hubei Province

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2026-03-01
Completion
2026-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07050212 on ClinicalTrials.gov